prikaz prve stranice dokumenta Učinkovitost intravitrealne terapije anti-VEGF lijekovima u KBC-u Split
  Download
PDF 603.84 KB
master's thesis
Učinkovitost intravitrealne terapije anti-VEGF lijekovima u KBC-u Split
2020. urn:nbn:hr:171:259973
Milardović, Anđela
University of Split
School of Medicine
Ophthalmology

Cite this document

Milardović, A. (2020). Učinkovitost intravitrealne terapije anti-VEGF lijekovima u KBC-u Split (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:259973

Milardović, Anđela. "Učinkovitost intravitrealne terapije anti-VEGF lijekovima u KBC-u Split." Master's thesis, University of Split, School of Medicine, 2020. https://urn.nsk.hr/urn:nbn:hr:171:259973

Milardović, Anđela. "Učinkovitost intravitrealne terapije anti-VEGF lijekovima u KBC-u Split." Master's thesis, University of Split, School of Medicine, 2020. https://urn.nsk.hr/urn:nbn:hr:171:259973

Milardović, A. (2020). 'Učinkovitost intravitrealne terapije anti-VEGF lijekovima u KBC-u Split', Master's thesis, University of Split, School of Medicine, accessed 13 April 2025, https://urn.nsk.hr/urn:nbn:hr:171:259973

Milardović A. Učinkovitost intravitrealne terapije anti-VEGF lijekovima u KBC-u Split [Master's thesis]. Split: University of Split, School of Medicine; 2020 [cited 2025 April 13] Available at: https://urn.nsk.hr/urn:nbn:hr:171:259973

A. Milardović, "Učinkovitost intravitrealne terapije anti-VEGF lijekovima u KBC-u Split", Master's thesis, University of Split, School of Medicine, Split, 2020. Available at: https://urn.nsk.hr/urn:nbn:hr:171:259973

Please login to the repository to save this object to your list.
Metadata
TitleUčinkovitost intravitrealne terapije anti-VEGF lijekovima u KBC-u Split
Title (english)Efficacy of intravitreal anti-VEGF therapy in KBC Split
AuthorAnđela Milardović
MentorLjubo Znaor (mentor)
Committee memberIvana Mudnić (predsjednik povjerenstva)
Committee memberAna Šešelja Perišin (član povjerenstva)
Committee memberRenata Pecotić (član povjerenstva)
GranterUniversity of Split
School of Medicine
(Ophthalmology)
Split
Defense date and country2020, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Ophthalmology
Abstract
Cilj istraživanja: Utvrditi koliko vremenski interval između indikacije i primjene anti-VEGF terapije utječe na ishod liječenja na Klinici za očne bolesti u Kliničkom bolničkom centru Split. Ispitanici i metode: Provedeno je retrospektivno istraživanje koje je uključivalo ukupno 172 bolesnika koji su primili intravitrealno bevacizumab. 116 bolesnika je liječeno zbog AMD te 56 zbog DME. Period obuhvata studije je od ožujka 2016. do studenog 2019. Istraživanje je provedeno na Klinici za očne... More bolesti KBC-a Split. Bolesnici su bili liječeni s tri doze bevacizumaba svakih mjesec dana uz kontrolu mjesec dana nakon primitka zadnje doze lijeka. OCT nalaz (analizirane vrijednosti: CST, Tmax ,CV i CAT) je napravljen kod postavljanja indikacije i nakon liječenja. Rezultati: Rezultati naše retrospektivne studije pokazuju da je došlo do smanjenja analiziranih vrijednosti (CST, Tmax, CV, CAT) i kod bolesnika s AMD i DME dijagnozom. U prosjeku je smanjenje vrijednosti nakon terapije CST (-34,91 µm), T-max (-81,12 µm), CV (-0,48 µm) i CAT (-13,52 µm) kod bolesnika s AMD , a kod bolesnika s DME u prosjeku je smanjenje vrijednosti CST (-38,18 µm), T-max (-54,71 µm), CV (-0,61 µm) i CAT (-11,07 µm). Utvrđena je povezanost između vremenskog intervala i CST, CV i CAT vrijednosti kod bolesnika s dijagnozom DME, povećanje vremenskog intervala između indikacije i primjene anti-VEGF terapije dovodi do povećanja CST, CV i CAT u bolesnika s DME. Kod bolesnika s AMD vremenski interval nije bio u korelaciji s ishodom liječenja: CST (r=0.02; P=0.397), Tmax (r=0.09; P=0.161), CV (r=0,04; P=0,346), CAT (r=0,05; P=0,289). Kod bolesnika s DME utvrđena je učinkovitost terapije kod primjene unutar 130 dana od indikacije. Zaključci: Tromjesečna intravitrealna injekcija bevacizumaba dovodi do poboljšanja u analiziranim vrijednostima OCT nalaza bolesnika sa dijagnozom senilne makularne degenercije i dijabetičnog makularnog edema. Također, bolesnicima s DME dijagnozom važno je pravovremeno primijeniti anti-VEGF terapiju te je učinkovitost veća ukoliko je terapija primijenjena unutar 130 dana od indikacije. Kod bolesnika s AMD vremenski interval nije bio u korelaciji s ishodom liječenja. Less
Abstract (english)
Objectives: The aim of this study was to determine the impact of intravitreal injection timing (i.e. the time interval from indication to application of anti-VEGF therapy) on treatment outcome at the Department of Ophthalmology, University Hospital Centre Split. Subjects and Methods: A retrospective study involving 172 patients who received intravitreal bevacizumab was performed. 116 patients were treated for AMD and 56 were treated for DME. Patients were treated between March 2016 and... More November 2019 at the Department of Ophthalmology, University Hospital Centre Split. Patients were treated with three (3) monthly doses of bevacizumab and follow-up was scheduled a month after receiving the last dose. OCT parameters analysed (CST, Tmax , CV and CAT) before and after therapy. Results: The results of our retrospective study has shown decline in CST, Tmax, CV and CAT values for both, AMD and DME patients. On average, there was a decline in values of CST (-34,91 µm), T-max (-81,12 µm), CV (-0,48 µm) and CAT (-13,52 µm) for AMD patients and for DME patients average decline was for CST (-38.18 µm), T-max (-54.71 µm), CV (-0.61 µm ) and CAT (-11.07 µm). Significant correlation between time interval and CST, CV and CAT values was found in DME patients, increasing the time interval between indication and application of anti-VEGF therapy leads to CST, CV, and CAT increase in patients with DME. The intravitreal injection timing is not in a significant correlation with the treatment outcome for AMD patients: CST (r=0.02; P=0.397), Tmax (r=0.09; P=0.161), CV (r=0,04; P=0,346), CAT (r=0,05; P=0,289). In patients with DME, the efficacy of the therapy is confirmed if applied within 130 days after indication. Conclusions: Three-month intravitreal injection of bevacizumab leads to an improvement of the analyzed OCT values in all patients. Also, for patients with DME diagnosis is important to apply timely anti-VEGF therapy and efficacy is higher if therapy is applied within 130 days after indication. The intravitreal injection timing wasn't in a significant correlation with the treatment outcome for AMD patients. Less
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:171:259973
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2020-09-15 10:25:33
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.